511 related articles for article (PubMed ID: 3113300)
1. [New thrombolytic agents].
Nguyen G; Samama M
Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
[TBL] [Abstract][Full Text] [Related]
2. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
3. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Samama M; Nguyen G; Desnoyers P; Lourenco DM; Fretault J; Horellou MH; Conard J; Szwarcer E; Verdy E; Vahanian A
Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
[TBL] [Abstract][Full Text] [Related]
4. New developments in thrombolytic therapy.
Collen D; Gold HK
Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
[TBL] [Abstract][Full Text] [Related]
5. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
6. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
7. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
8. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
9. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
10. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
13. [Anistreplase. Pharmacology and biological data].
Samama M
Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():15-20. PubMed ID: 2108641
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic agents: mechanisms of activity and pharmacology.
Lijnen HR; Collen D
Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
[TBL] [Abstract][Full Text] [Related]
16. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
Crabbe SJ; Grimm AM; Hopkins LE
Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic therapy.
Collen D; Stump DC; Gold HK
Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
[TBL] [Abstract][Full Text] [Related]
18. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
20. The acyl-enzymes and pro-urokinase: promising new thrombolytic agents.
Samama M; Horellou MH; Nguyen G; Conard J
Haemostasis; 1986; 16 Suppl 3():33-7. PubMed ID: 3095196
[No Abstract] [Full Text] [Related]
[Next] [New Search]